CN113620834B - Allium macrostemon medicinal material extract, extraction method, preparation method and application - Google Patents
Allium macrostemon medicinal material extract, extraction method, preparation method and application Download PDFInfo
- Publication number
- CN113620834B CN113620834B CN202110776103.7A CN202110776103A CN113620834B CN 113620834 B CN113620834 B CN 113620834B CN 202110776103 A CN202110776103 A CN 202110776103A CN 113620834 B CN113620834 B CN 113620834B
- Authority
- CN
- China
- Prior art keywords
- allium macrostemon
- ethyl acetate
- amide
- petroleum ether
- allium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000304531 Allium macrostemon Species 0.000 title claims abstract description 186
- 239000000463 material Substances 0.000 title claims abstract description 51
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 238000000605 extraction Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 35
- 150000001408 amides Chemical class 0.000 claims abstract description 107
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 179
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 100
- 239000003208 petroleum Substances 0.000 claims description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- 239000002904 solvent Substances 0.000 claims description 48
- 238000004809 thin layer chromatography Methods 0.000 claims description 48
- 238000010828 elution Methods 0.000 claims description 43
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 42
- 239000003480 eluent Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000010898 silica gel chromatography Methods 0.000 claims description 23
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 125000001033 ether group Chemical group 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 abstract description 13
- 230000002107 myocardial effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 9
- 230000009897 systematic effect Effects 0.000 abstract description 6
- 239000000178 monomer Substances 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 description 64
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 43
- -1 amide compounds Chemical class 0.000 description 39
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- 239000001257 hydrogen Substances 0.000 description 31
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 11
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000005100 correlation spectroscopy Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 4
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 4
- 230000008065 myocardial cell damage Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 244000295724 Allium chinense Species 0.000 description 1
- 235000016790 Allium chinense Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C243/32—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C241/04—Preparation of hydrazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an allium macrostemon medicinal material extract, an extraction method, a preparation method and application thereof, wherein the allium macrostemon medicinal material is subjected to systematic and deep chemical composition research, and 2 amide components allium macrostemon amide A and allium macrostemon amide B which are novel compounds are separated from the allium macrostemon medicinal material for the first time, and the extraction method, the preparation method and the application of the extract in the aspect of myocardial cell protection activity are defined. Solves the problems that no literature report of the systematic study of the medium-polarity chemical components of the allium macrostemon medicinal materials exists at home and abroad, and no report related to the preparation method and the application of two monomer compounds with novel structures separated from the allium macrostemon medicinal materials is also found.
Description
Technical Field
The invention relates to the field of natural medicine invention, in particular to a allium macrostemon medicinal material extract, an extraction method, a preparation method and application.
Background
Bulbus Allii Macrostemi is bulb of Bulbus Allii Macrostemi (Allium chinense G.don) or Bulbus Allii Cepae (Allium macrostemon Bunge) of genus Liliaceae (Liliaceae). (national pharmacopoeia Committee. One of the Chinese pharmacopoeias of the people's republic of China, edition one of the Pharmacopeia 2020, beijing: china medical science and technology Press, 2020:392.) as a traditional medicine and food dual purpose plant, was originally carried in Shennong Ben Cao Jing, listed as a Chinese medicine, and recorded in Ben Cao gang mu for treating "Shaoyin disease, syncope, diarrhea, chest stuffiness and stinging, qi-flowing and blood-dispelling". Is mainly distributed in northeast China, north China, korean and Japan. The former research on the allium macrostemon chemical components mainly focuses on the research on the steroid saponin with large polarity and the qualitative analysis of volatile oil parts, and in the aspect of pharmacological activity research, the allium macrostemon volatile oil is found to have pharmacological activities of inhibiting platelet aggregation, resisting atherosclerosis and the like (Cheng Yanhua, li Mengmeng, guo Yunlong, huang Xin, more bright, chen Changbao, wang Zhongxi, liu Dong, yang Dehui. The allium macrostemon chemical components and the extraction and separation research thereof progress [ J ]. Special product research, 2020,42 (05): 61-70).
At present, no literature report exists on the systematic study of the medium-polarity chemical components of the allium macrostemon medicinal materials at home and abroad, and no report related to the preparation method and the application of two monomer compounds with novel structures, which are separated from the allium macrostemon medicinal materials.
In order to overcome the technical problems, the inventor conducts systematic and intensive chemical component research on the allium macrostemon, 2 amide components are separated from the allium macrostemon and are novel compounds, and an extraction method, a preparation method and application of the extract in the aspect of in-vitro myocardial cell protection activity are defined.
Disclosure of Invention
The invention aims to provide an allium macrostemon medicinal material extract.
The invention further aims at providing a method for extracting allium macrostemon medicinal materials.
The invention also aims at providing a preparation method of the allium macrostemon medicinal material.
The invention also aims at providing an application of allium macrostemon amide A, B in preparation of a preparation for treating coronary heart disease.
The extracts of the allium macrostemon medicinal materials are allium macrostemon amide A and allium macrostemon Bai Xianan B, and the structures of the allium macrostemon amide A and allium macrostemon Bai Xianan B are as follows: 1) Allium macrostemon Bai Xianan a:
2) Allium macrostemon Bai Xianan B:
the extraction method of the allium macrostemon medicinal material extract comprises the following steps of:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 2 to 6 times at 60 to 90 ℃ with 5 to 10 times of 95 percent ethanol for 2 to 4 hours each time, combining the materials to obtain an extracting solution, recovering a solvent, and concentrating to obtain the total concentrated solution of the allium macrostemon medicinal materials;
2) Suspending the total concentrated liquid extract in 2-7 times of water for dilution, sequentially extracting with 2-7 times of petroleum ether, ethyl acetate and n-butanol for 2-5 times respectively, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
Preferably, the method for extracting the allium macrostemon medicinal material extract comprises the following steps of:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 2 to 5 times at the temperature of between 65 and 85 ℃ with 6 to 9 times of 95 percent ethanol for 2 to 4 hours each time, combining the materials to obtain an extracting solution, recovering a solvent, and concentrating to obtain the total concentrated solution of the allium macrostemon medicinal materials;
2) Suspending the total concentrated liquid extract in 2-6 times of water for dilution, sequentially extracting with 2-6 times of petroleum ether, ethyl acetate and n-butanol for 2-4 times respectively, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
Still preferably, the method for extracting the allium macrostemon medicinal material extract of the invention comprises the following steps:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 3-4 times at 80 ℃ with 8 times of 95% ethanol for 2-4 hours each time, combining the extracting solutions, recovering the solvent, and concentrating to obtain the allium macrostemon medicinal material total concentrated solution;
2) Suspending the total concentrated liquid extract in 3-5 times of water for dilution, sequentially extracting with 3-5 times of petroleum ether, ethyl acetate and n-butanol for 3 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
The allium macrostemon amide A and B elution fractions obtained in the step 4) in the extraction method are prepared by high performance liquid chromatography, and the allium macrostemon Bai Xianan A and B elution fractions are respectively eluted by 5-15L of 20-40% methanol to obtain compounds allium macrostemon amide A and allium macrostemon amide B.
The preparation method of the extract comprises the steps of preparing allium macrostemon amide A eluting flow through high performance liquid chromatography, eluting with 30% methanol and 10L to obtain the compound allium macrostemon amide A.
The preparation method of the extract comprises the steps of preparing allium macrostemon amide B elution flow through high performance liquid chromatography, eluting with 25% methanol and 10L to obtain the compound allium macrostemon amide B.
The invention relates to application of allium macrostemon amide A, B in preparation of a preparation for treating coronary heart disease.
The preparation is prepared by adding pharmaceutically acceptable auxiliary materials.
The preparation is a solid preparation or a liquid preparation.
The preparation is prepared by adding pharmaceutically acceptable auxiliary materials, the solid preparation is granules, capsules, powder, tablets, pills and the like, and the liquid preparation is oral liquid, injection and the like.
The pharmaceutically acceptable auxiliary materials are not limited, and can be accepted in pharmacy.
Problems of the prior art the invention has the following beneficial effects:
1. problems of the prior art
At present, no literature report exists on the systematic study of the medium-polarity chemical components of the allium macrostemon medicinal materials at home and abroad, and no report related to the preparation method and the application of two monomer compounds with novel structures, which are separated from the allium macrostemon medicinal materials.
2. The beneficial effects of the invention are that
1. The invention discloses allium macrostemon medicinal material extracts, allium macrostemon amide A and allium macrostemon amide B for the first time; and provides the extraction and separation method and the structure confirmation process of the allium macrostemon, perfects the research of allium macrostemon chemical components and enriches the diversity of amide compounds.
2. The inventor conducts systematic and deep chemical component research on allium macrostemon medicinal materials, 2 amide components are separated from the allium macrostemon medicinal materials, are all novel amide compounds, and define an extraction method and a preparation method of the extract and application of the extract in the aspect of in-vitro myocardial cell protective activity.
3. The invention uses the extract to treat H 2 O 2 The results of the test for the effect of induced H9c2 cell viability showed that: h compared with the normal control group 2 O 2 The survival rate of the induced H9c2 cell damage model group (CH) cells was reduced to 49.68% (P)<0.0001 Compared with the model group, the survival rate of H9c2 cells is obviously improved to 63.44% (P) by the intervention of an ethyl acetate part (XB-EA) sample<0.01 The protective effect on the rat myocardial cell injury induced by hydrogen peroxide is remarkable, which indicates that the protective effect on the rat myocardial cell injury has a certain myocardial cell protective activity.
4. The invention is realized byExtract pair H 2 O 2 The results of the test for the effect of induced H9c2 cell viability showed that: h compared with the normal control group 2 O 2 The survival rate of the induced H9c2 cell damage model group (CH) cells was reduced to 49.68% (P)<0.0001 Compared with the model group, the allium macrostemon amide A intervention improves the survival rate of H9c2 myocardial cells to 52.29 percent, the allium macrostemon Bai Xianan B intervention improves the survival rate of H9c2 myocardial cells to 55.64 percent, which indicates that the compound has myocardial cell protection activity.
Drawings
Allium macrostemon amide A of FIG. 1 1 H-NMR spectrum.
FIG. 2 allium macrostemon amide A 13 C-NMR and DEPT spectra.
FIG. 3 allium macrostemon amide A 1 H- 1 H COSY pattern.
FIG. 4 HSQC spectrum of allium macrostemon amide A.
FIG. 5 HMBC pattern of allium macrostemon amide A.
FIG. 6 NOESY spectrum of allium macrostemon amide A.
FIG. 7 high resolution mass spectrum of HR-ESI-MS of allium macrostemon amide A.
FIG. 8 allium macrostemon amide B 1 H-NMR spectrum.
FIG. 9 allium macrostemon amide B 13 C-NMR and DEPT spectra.
FIG. 10 allium macrostemon amide B 1 H- 1 H COSY pattern.
FIG. 11 HSQC spectrum of allium macrostemon amide B.
FIG. 12 HMBC pattern of allium macrostemon amide B.
FIG. 13 NOESY spectrum of allium macrostemon amide B.
FIG. 14 HR-ESI-MS high-resolution mass spectrum of allium macrostemon amide B.
FIG. 15 total extract of Bulbus Allii Macrostemi (ZT), petroleum Ether (PE), ethyl Acetate (EA), n-butanol (Bu-OH), water extraction (H) 2 O), allium macrostemon amide a and allium macrostemon amide B inhibited hydrogen peroxide-induced myocardial cell damaging activity in rat H9c 2.
Detailed Description
The following examples are illustrative of the invention and are not intended to limit the scope of the invention.
Example 1 allium macrostemon amide A, B, their structures are as follows:
1) Allium macrostemon Bai Xianan a:
2) Allium macrostemon Bai Xianan B:
EXAMPLE 2 extraction method of allium macrostemon amide A, B
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 3-4 times at 80 ℃ with 8 times of 95% ethanol for 2-4 hours each time, combining the extracting solutions, recovering the solvent, and concentrating to obtain the allium macrostemon medicinal material total concentrated solution;
2) Suspending the total concentrated liquid extract in 3-5 times of water for dilution, sequentially extracting with 3-5 times of petroleum ether, ethyl acetate and n-butanol for 3 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
EXAMPLE 3 extraction method of allium macrostemon amide A, B
1) Drying Bulbus Allii Macrostemi, pulverizing, reflux extracting with 6 times of 95% ethanol at 65deg.C for 2 hr each time, mixing to obtain extractive solutions, recovering solvent, and concentrating to obtain total concentrated solution of Bulbus Allii Macrostemi;
2) Suspending the total concentrated liquid extract in 2 times of water for dilution, sequentially extracting with 2 times of petroleum ether, ethyl acetate and n-butanol for 2 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
EXAMPLE 4 extraction method of allium macrostemon amide A, B
1) Drying Bulbus Allii Macrostemi, pulverizing, reflux extracting with 9 times of 95% ethanol at 85deg.C for 5 times each for 4 hr, mixing to obtain extractive solutions, recovering solvent, and concentrating to obtain total concentrated solution of Bulbus Allii Macrostemi;
2) Suspending the total concentrated liquid extract in 6 times of water for dilution, sequentially extracting with 6 times of petroleum ether, ethyl acetate and n-butanol for 4 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
Example 5 extraction method of allium macrostemon amide A, B
1) Drying Bulbus Allii Macrostemi, pulverizing, reflux extracting with 5 times of 95% ethanol at 60deg.C for 2 hr each time, mixing to obtain extractive solutions, recovering solvent, and concentrating to obtain total concentrated solution of Bulbus Allii Macrostemi;
2) Suspending the total concentrated liquid extract in 2 times of water for dilution, sequentially extracting with 2 times of petroleum ether, ethyl acetate and n-butanol for 2 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
EXAMPLE 6 extraction method of allium macrostemon amide A, B
1) Drying Bulbus Allii Macrostemi, pulverizing, reflux extracting with 10 times of 95% ethanol at 90deg.C for 6 times each for 4 hr, mixing to obtain extractive solutions, recovering solvent, and concentrating to obtain total concentrated solution of Bulbus Allii Macrostemi;
2) Suspending the total concentrated extract in 7 times of water for dilution, sequentially extracting with 7 times of petroleum ether, ethyl acetate and n-butanol for 5 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
EXAMPLE 7 preparation method of allium macrostemon amide A, B
The eluted fraction of allium macrostemon amide A in any of examples 1-6 was prepared by high performance liquid chromatography eluting with 30% methanol 10L to give allium macrostemon amide A.
EXAMPLE 8 preparation method of allium macrostemon amide A, B
The eluted fraction of allium macrostemon amide A in any of examples 1-6 was prepared by high performance liquid chromatography and eluted with 30% methanol 5L to give allium macrostemon amide A.
EXAMPLE 9 preparation method of allium macrostemon amide A, B
The eluted fraction of allium macrostemon amide A in any of examples 1-6 was prepared by high performance liquid chromatography eluting with 30% methanol 15L to give allium macrostemon amide A.
EXAMPLE 10 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 20% methanol 10L to obtain the compound allium macrostemon amide A.
EXAMPLE 11 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 20% methanol 5L to obtain the compound allium macrostemon amide A.
EXAMPLE 12 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 20% methanol 15L to obtain the compound allium macrostemon amide A.
EXAMPLE 13 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 40% methanol 10L to obtain the compound allium macrostemon amide A.
EXAMPLE 14 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 40% methanol 5L to obtain the compound allium macrostemon amide A.
EXAMPLE 15 preparation method of allium macrostemon amide A, B
The eluted fraction of the allium macrostemon amide A in the examples 1-6 is prepared by high performance liquid chromatography and eluted with 40% methanol 15L to obtain the compound allium macrostemon amide A.
Example 16 extraction and preparation methods of allium macrostemon Bai Xianan A and B
Drying and pulverizing Bulbus Allii Macrostemi (46.9 kg), reflux extracting with 95% ethanol (feed-liquid ratio 1:8) at 80deg.C for 3 times (4, 2 h), recovering solvent, and concentrating to obtain Bulbus Allii Macrostemi concentrated solution (2.2 kg); suspending the total concentrated liquid extract in 3-5 times of water, sequentially extracting with 3-5 times of petroleum ether, ethyl acetate and n-butanol for 3 times, and recovering solvent under reduced pressure to obtain petroleum ether part (180 g), ethyl acetate part (320 g) and n-butanol part (500 g) respectively.
Loading 320g of ethyl acetate part of Bulbus Allii Macrostemi onto normal phase silica gel column (100-200 mesh), sequentially gradient eluting with petroleum ether-ethyl acetate (100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate), detecting the eluate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 eluate parts.
Continuing the subdivision, take 4:1 elution fraction (27.2 g), dissolved in petroleum ether and ethyl acetate, was stirred with silica gel (200-300 mesh) 1.5 times the mass of the extract. Eluting with silica gel column chromatography from petroleum ether-ethyl acetate (10:1), monitoring in real time by Thin Layer Chromatography (TLC), gradually increasing the polarity of the eluent, detecting to find that the compound basically flows out when petroleum ether-ethyl acetate (1:1), and stopping passing through the column. Detecting by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 5 eluate fractions.
Following the preparation procedure, the 1 st elution fraction (305 mg) was dissolved with chromatographically pure methanol, and a very small amount was dissolved, diluted to about 10mg/ml, and detected by High Performance Liquid Chromatography (HPLC) using 10% -100% MEOH-20min, a large absorption peak (210 nm) was observed at 17min, a large absorption peak (210 nm) was found at 15min, and then eluted with 30% methanol (10L) by preparative HPLC to give the compound allium macrostemon A (25.0 mg).
The 2 nd elution fraction (203 mg) was dissolved with chromatographically pure methanol, and a very small amount of the solution was taken out, diluted to about 10mg/ml, and subjected to sample injection detection by High Performance Liquid Chromatography (HPLC) using 10% -100% MEOH-20min, a large absorption peak (detection wavelength: 210 nm) was observed at 15min, and then eluted with 25% methanol (10L) by preparative HPLC to give the compound allium macrostemon amide B (20.7 mg).
Allium macrostemon amide A, B 1 H-NMR 13 The C-NMR data are shown in Table 1 and Table 2, respectively.
TABLE 1 allium macrostemon amide A 1 H-NMR, 13 C-NMR data
TABLE 2 allium macrostemon amide B 1 H-NMR, 13 C-NMR data
The atomic numbers of the compounds are shown in a structural formula diagram of the compounds; the nuclear magneto-chemical shift unit is ppm.
Allium macrostemon Bai Xianan a: a pale yellow oil, dissolved in chloroform, was prepared by ESI-MS: m/z 625[ M+H ]] + The molecular weight is estimated to be 624, and the molecular formula is determined to be C by combining a one-dimensional map 36 H 36 N 2 O 8 By HR-ESI-MS: m/z 647.2513[ M+Na ]] + (calcd.for 647.2499) confirmed that Ω=20, and the structure was presumed to have a multi-benzene ring structure.
In one-dimensional hydrogen spectrum, two groups of trans double bond methine proton signals [ delta ] exist in low field region H 7.43(1H,d,J＝15.7Hz),6.40(1H,d,J＝15.7Hz)]，[δ H 6.61(1H,d,J＝12.6Hz),5.81(1H,d,J＝12.6Hz)]And two sets of benzene ring 1,3, 4-trisubstituted characteristic aryl proton signals [ delta ] H 7.35(1H,d,J＝1.9Hz),6.92(1H,dd,J＝8.2,1.9Hz),6.73(1H,d,J＝8.2Hz)]，[δ H 7.11(1H,d,J＝1.8H),7.02(1H,dd,J＝8.2,1.8Hz),6.79(1H,d,J＝8.2Hz)]Two groups of para-position substitution characteristic aryl proton signals [ delta ] of benzene rings exist at the same time H 7.05(2H,d,J＝8.4Hz),6.71(2H,J＝8.4Hz)]，[δ H 6.99(2H,d,J＝8.3Hz),6.68(2H,J＝8.3Hz)]In addition to this, two sets of methoxy proton signals [ delta ] exist H 3.88(3H,s)]，[δ H 3.82(3H,s)]There are also two sets of respectively linked methylene proton signals [ delta ] in the high field region H 3.46(2H,t,J＝7.4Hz),2.75(2H,t,J＝7.4Hz)]，[δ H 3.39(2H,t,J＝7.4Hz),2.69(2H,t,J＝7.4Hz)]There are 6 remaining unassigned protons, presumably amine or hydroxyl groups in the structure.
One-dimensional carbon spectrum and DEPT spectrum show that the compound has 2 amide carbonyl carbon signals [ delta ] in low field region C 168.8,167.7]In combination with the two-dimensional HSQC spectrum, there are two sets of double bond methine carbon signals [ delta ] C 140.5,117.3]，[δ C 136.9,120.2]Two groups of benzene rings para-position substituted double bond methine carbon signals [ delta ] C 129.3,114.8]，[δ C 129.2,114.8]Two groups of benzene rings 1,3, 4-trisubstituted characteristic methine carbon signals [ delta ] C 123.4,114.4,112.5]，[δ C 121.7,115.0,110.1]And benzene ring quaternary carbon signal [ delta ] C 155.5,155.4,148.4,147.8,147.1,147.0,129.8,129.7,127.1,126.8]Wherein the benzene ring quaternary carbon signal [ delta ] C 155.5,155.4,148.4,147.8,147.1,147.0]At the lower field, presumably linked to a hydroxyl or methoxy group. At the same time there are also 2 methoxy carbon signals [ delta ] C 54.9,54.9]And two sets of methylene carbon signals [ delta ] C 41.1,34.3]，[δ C 40.92,34.1]。
In the two-dimensional map by 1 H- 1 H COSY pattern [ H-3/H-4 ]]，[H-3'/H-4']，[H-6/H-9,H-9/H-10]，[H-6'/H-9',H-9'/H-10']，[H-11/H-12]，[H-11'/H-12']Is in between with 1 H- 1 H COSY signal.
In the HMBC pattern, there are signals that double bond methine hydrogen (H-3) has a correlation signal to double bond methine carbon (C-4), benzene ring methine (C-6) and (C-10), and benzene ring quaternary carbon (C-5) and amide carbonyl (C-2), double bond methine hydrogen (H-4) has a correlation signal to benzene ring quaternary carbon (C-5) and amide carbonyl (C-2), benzene ring methine hydrogen (H-6) has a correlation signal to benzene ring quaternary carbon (C-8), double bond methine carbon (C-3) benzene ring methine carbon (C-10), benzene ring methine hydrogen (H-9) has a correlation signal to benzene ring quaternary carbon (C-7) and benzene ring quaternary carbon (C-5), benzene ring methine hydrogen (H-10) has a correlation signal to benzene ring quaternary carbon (C-8), benzene ring methine carbon (C-6) and double bond methine carbon (C-3), methoxy hydrogen signal has a correlation signal to (C-7), and (C-7) is connected to methoxy group (C-8), and (C-8) is connected to (CH-3) may be 3 to (CH-4) - (3) ].
On the other side, the benzene ring methine hydrogen (H-15, H-17) has related signals to benzene ring methine carbon (C-14, C-18) and benzene ring quaternary carbon (C-16), the benzene ring methine hydrogen (H-14, H-18) has related signals to benzene ring methine carbon (C-15, C-17) and benzene ring quaternary carbon (C-16) and benzene ring quaternary carbon (C-13), the methylene hydrogen (H-11) has related signals to methylene carbon (C-12), amide carbonyl carbon (C-2) and benzene ring quaternary carbon (C-13), the methylene hydrogen (H-12) has related signals to methylene carbon (C-11) and benzene ring quaternary carbon (C-13), the fragment 2 can be [ -CO (2) -CH 2 (11)-CH 2 (12)-(16-hydroxyphenyl)]。
At the same time, the phenylmethyne hydrogen (H-6 ') has a correlation signal to the phenylquaternary carbon (C-8'), the double bond methyne carbon (C-3 ') and the phenylmethyne carbon (C-10'), the phenylmethyne hydrogen (H-9 ') has a correlation signal to the phenylquaternary carbon (C-5') and the phenylquaternary carbon (C-7 '), the phenylmethyne hydrogen (H-10') has a correlation signal to the phenylquaternary carbon (C-8 '), the phenylmethyne carbon (C-6') and the double bond methyne carbon (C-3 '), the methoxyhydrogen signal has a correlation signal to (C-7'), the double bond methyne hydrogen (H-3 ') has a correlation signal to the double bond methyne carbon (C-4'), the phenylmethyne hydrogen (C-6 ') and (C-10'), and the amide carbonyl (C-2 '), and the double bond methyne hydrogen (H-4') has a correlation signal to the phenylquaternary carbon (C-5 '), and the amide carbonyl (C-2'), so that a very weak correlation signal exists to obtain a segment of (3 '-oxymethylene H-3') and (CH-3 '-oxych-3') (3 '-oxych-3')canbe obtained.
On the other side, the phenylmethine hydrogen (H-15 ', H-17 ') has related signals to the phenylmethine carbon (C-14 ', C-18 ') and the phenylquaternary carbon (C-16 '), and the phenylmethine hydrogen (H-14 ', H-18 ') has related signals to the phenylmethine carbon (C-15 ', C-17 '), and the phenylquaternary carbon (C-16 ') and the phenylquaternary carbon (C-13 '), and the methylenehydrogen (H-11 ') has related signals to the methylenecarbon (C-12 '), and the aminocarbonyl groupThe related signals of the carbon (C-2 ') and the quaternary carbon of benzene ring (C-13') exist, and the related signals of the methylene hydrogen (H-12 ') on the methylene carbon (C-11') and the quaternary carbon of benzene ring (C-13 ') exist, so that the fragment 4 is [ -CO (2') -CH can be obtained 2 (11')-CH 2 (12')-(16'-hydroxyphenyl)]。
Since the HMBC related signals are present in (H-4), (H-3) and (H-11) on the amide carbonyl group (C-2) in the HMBC pattern, the N atom has less interference on the HMBC, the HMBC related signals are presumed to be the quaternary amine structure, the HMBC related signals are present in (H-4 ') and (H-11 ') on the amide carbonyl group (C-2), and the HMBC related signals are extremely weak in (H-3 ') on the amide carbonyl group (C-2), and the HMBC related signals are presumed to be the quaternary amine structure. Fragments (1+2) and (3+4) are therefore linked by a nitrogen-nitrogen bond. And according to the chemical shift of (C-11, C-12) (C-11 ', C-12 '), the (C-11) and (C-11 ') are respectively connected with nitrogen atoms, and the chemical environment is not equivalent due to the configuration of the nitrogen atoms, so that the carbon atoms show different chemical shift values. The final structure obtained is: (E) -3- (4-hydroxy-3-methoxyphenyl) -N '- ((E) -3- (4-hydroxy-3-methoxyphenyl) acyloyl) -N, N' -bis (4-hydroxy phenyl) acyloyl-amide, and designated allium macrostemon a.
Allium macrostemon Bai Xianan B: a pale yellow oil, dissolved in chloroform, was prepared by ESI-MS: m/z 336[ M+Na] + The molecular weight was estimated to be 313, and the molecular formula was determined to be C in combination with one-dimensional spectra 18 H 19 NO 4 Then by HR-ESI-MS: m/z 314.1419[ M+H ]] + (calcd.for 314.1392) confirmed that Ω=10, and the structure was presumed to have a multi-benzene ring structure.
In one-dimensional hydrogen spectrum, a group of trans double bond proton signals [ delta ] exist in a low field region H 7.45(1H,d,J＝15.6Hz),6.38(1H,d,J＝15.6Hz)]And a set of benzene ring 1,2, 3-trisubstituted characteristic aryl proton signals [ delta ] H 7.32(1H,d,J＝8.3Hz),7.09(1H,m),6.80(1H,d,J＝8.4Hz)]At the same time, a group of para-substitution characteristic aryl proton signals [ delta ] of benzene ring also exist H 7.06(2H,d,J＝8.5Hz),6.73(2H,J＝8.5Hz)]In addition to this, there is a set of methoxy proton signals [ delta ] H 3.83(3H,s)]There is also a set of linked methylene proton signals [ delta ] in the high field region H 3.48(2H,t,J＝7.3Hz),2.77(2H,t,J＝7.3Hz)]To remove
In addition to the upper 16 proton signals, it is presumed that an amine group or a hydroxyl group is present in the structure.
At the position of 13 In the C-NMR and DEPT spectra there are 1 amide carbonyl carbon signals [ delta ] in the low field region C 168.9]In combination with the two-dimensional HSQC spectrum, there is a set of double bond methine carbon signals [ delta ] C 140.7,117.3]Benzene ring para-substituted double bond methine carbon signal [ delta ] C 129.3,114.9]A group of benzene ring 1,2, 3-trisubstituted characteristic methine carbon signals [ delta ] C 121.9,115.1,110.1]And benzene ring quaternary carbon signal [ delta ] C 155.2,148.3,147.7,129.8,115.0]Wherein the benzene ring quaternary carbon signal [ delta ] C 55.2,148.3,147.7]At the lower field, presumably linked to a hydroxyl or methoxy group. At the same time there is also 1 methoxy carbon signal [ delta ] C 54.9]And two sets of methylene carbon signals [ delta ] C 41.0,34.3]。
First pass through in two-dimensional map 1 H- 1 H COSY pattern [ H-3/H-4 ]]，[H-8/H-9,H-9/H-10]，[H-11/H-12]With between 1 H- 1 H COSY signal. Meanwhile, in the HMBC pattern, the double bond methine hydrogen (H-3) has a response signal to the benzene ring methine (C-10) and the amide carbonyl (C-2), the double bond methine hydrogen (H-4) has a correlation signal to the benzene ring quaternary carbon (C-5) and the amide carbonyl (C-2), the benzene ring methine hydrogen (H-8) has a correlation signal to the benzene ring quaternary carbon (C-7), the benzene ring methine carbon (C-10), the benzene ring methine hydrogen (H-9) has a correlation signal to the benzene ring quaternary carbon (C-6) and the benzene ring quaternary carbon (C-5), the benzene ring methine hydrogen (H-10) has a correlation signal to the benzene ring quaternary carbon (C-9), the benzene ring quaternary carbon (C-6) and the double bond methine carbon (C-3), and the methoxy hydrogen signal has a correlation signal to (C-7), which indicates that (C-7) is connected with methoxy, and (C-6) is connected with hydroxy, so that we can obtain a fragment 1 which may be [ -CO (2) -CH (4) - (6-methoxy-7-phenyl-carbonyl]。
On the other side, the benzene ring methine hydrogen (H-15, H-17) has related signals to the benzene ring methine carbon (C-14, C-18) and the benzene ring quaternary carbon (C-16), and the benzene ring methine hydrogen (H-14, H-18) has related signals to the benzene ring methine carbon (C-15, C-17) and the benzene ring quaternary carbonThe related signals of the carbon (C-16) and the quaternary carbon of the benzene ring (C-13) exist, the related signals of the methylene hydrogen (H-11) to the methylene carbon (C-12), the amide carbonyl carbon (C-2) and the quaternary carbon of the benzene ring (C-13) exist, the related signals of the methylene hydrogen (H-12) to the methylene carbon (C-11) and the quaternary carbon of the benzene ring (C-13) exist, and the fragment 2 of [ -CO (2) -CH can be obtained 2 (11)-CH 2 (12)-(16-hydroxyphe nyl)]。
Based on the above data and the comparison with allium macrostemon amide A, the compound can be obtained as follows: (E) -3- (2-hydroxy-3-methoxyphenyl) -N- (4-hydroxy-phenyl) acrylic amide and designated allium macrostemon amide B.
In summary, it can be determined that the structures of the allium macrostemon amide A and the allium macrostemon amide B prepared by the method are as follows: (E) -3- (4-hydroxy-3-methoxyphenyl) -N '- ((E) -3- (4-hydroxy-3-methoxyphenyl) acrylic-yl) -N, N' -bis (4-hydroxy-phenyl) acrylic-hydroxy-zide, and (E) -3- (2-hydroxy-3-methoxyphenyl) -N- (4-hydroxy-phenyl) acrylic-amide.
Example 17
Taking allium macrostemon amide A or B as a raw material medicine, adding 1/8 of starch, and granulating to obtain granules.
In the embodiment 18, allium macrostemon amide A or B is taken as a raw material medicine, 1/10 of starch is added, and the mixture is uniformly mixed and filled into capsules to obtain capsules.
Example 19 Allium macrostemon amide A or B is taken as a raw material medicine, added with 1/10 of dextrin, mixed uniformly, dried and prepared into pills.
Example 20 allium macrostemon amide A or B is taken as a raw material drug, 1/8 of starch is added, and the mixture is granulated, pressed into tablets.
In example 21, allium macrostemon amide A or B is taken as a raw material medicine, 20 times of water for injection is added, and the injection is obtained by filtering and sterilizing.
In the embodiment 22, allium macrostemon amide A or B is taken as a raw material medicine, 5 times of water is added, and the oral liquid is obtained by filtering and sterilizing.
Example 23 total extract of allium macrostemon, petroleum ether, ethyl acetate, n-butanol, water extraction sites inhibited hydrogen peroxide-induced myocardial cell injury activity in rats H9c 2.
(1) Sample configuration
The total extract of allium macrostemon, petroleum ether, ethyl acetate, n-butanol and water extracted parts prepared in example 16 are dissolved by DMSO (dimethyl sulfoxide) (Merck), and then PBS (phosphate buffer solution) is added to prepare a solution of 10mg/mL, and the solution is further diluted into samples with different gradient concentrations. 200 mu M hydrogen peroxide was used as inducer.
(2) Experimental method
H9c2 cells (given from Beijing university of Chinese medicine) are adherent growth cells routinely cultured in DMEM medium containing 10% fetal bovine serum, 5% CO 2 Culturing in a constant temperature incubator at 37 ℃. In the experiment, the original medium was discarded, and 100. Mu.L of the complete medium of the dissolved test compound was added to the culture medium at a final concentration of 50. Mu.g/mL per well and returned to the incubator. After 1H, 5. Mu.L of H was added per well to a final concentration of 200. Mu.M 2 O 2 And (5) placing the mixture back into an incubator for culturing for 24 hours. After 24h, MTT reagent was added in the dark to give a final concentration of 500. Mu.g/mL. After further culturing for 4 hours, the supernatant was aspirated, 100. Mu.L of DMSO was added to each well, and after dissolving in the dark for 10 minutes, the absorbance was measured.
(3) Evaluation criterion and statistical method
Absorbance was measured at 570nm, the data obtained were analyzed using GraphPad 8.0, the values were expressed as mean ± standard deviation, the data between the multiple sets were compared using one-way analysis of variance, and the data between the two sets were tested using t-test.
(4) Experimental results
Extract pair H 2 O 2 Effect of induced H9c2 cell viability: h compared with the normal control group 2 O 2 The survival rate of the induced H9c2 cell damage model group (CH) cells was reduced to 49.68% (P)<0.0001 Compared with the model group, the survival rate of H9c2 cells is obviously improved to 63.44% (P) by the intervention of an ethyl acetate part (XB-EA) sample<0.01 Has remarkable protective effect on rat myocardial cell injury induced by hydrogen peroxide (the result is shown in figure 15).
Example 24 allium macrostemon amide a, B inhibited hydrogen peroxide-induced myocardial cell damaging activity in rat H9c 2.
(1) Sample configuration
After the allium macrostemon amides A and B (dimethyl sulfoxide) (Merck) prepared in examples 2-10 were dissolved, PBS (phosphate buffer solution) was added to prepare a 10mg/mL solution, which was further diluted into samples of different gradient concentrations. 200 mu M hydrogen peroxide was used as inducer.
(2) Experimental method
H9c2 cells (given from Beijing university of Chinese medicine) are adherent growth cells routinely cultured in DMEM medium containing 10% fetal bovine serum, 5% CO 2 Culturing in a constant temperature incubator at 37 ℃. In the experiment, the original medium was discarded, and 100. Mu.L of the complete medium of the dissolved test compound was added to the culture medium at a final concentration of 50. Mu.M per well and returned to the incubator. After 1H, 5. Mu.L of H was added per well to a final concentration of 200. Mu.M 2 O 2 And (5) placing the mixture back into an incubator for culturing for 24 hours. After 24h, MTT reagent was added in the dark to give a final concentration of 500. Mu.g/mL. After further culturing for 4 hours, the supernatant was aspirated, 100. Mu.L of DMSO was added to each well, and after dissolving in the dark for 10 minutes, the absorbance was measured.
(3) Evaluation criterion and statistical method
Absorbance was measured at 570nm, the data obtained were analyzed using GraphPad 8.0, the values were expressed as mean ± standard deviation, the data between the multiple sets were compared using one-way analysis of variance, and the data between the two sets were tested using t-test.
(4) Experimental results
Extract pair H 2 O 2 Effect of induced H9c2 cell viability: h compared with the normal control group 2 O 2 The survival rate of the induced H9c2 cell damage model group (CH) cells was reduced to 49.68% (P)<0.0001 Compared with the model group, the intervention of allium macrostemon amide A improves the survival rate of H9c2 myocardial cells to 52.29 percent, the intervention of allium macrostemon Bai Xianan B improves the survival rate of H9c2 myocardial cells to 55.64 percent, and has certain myocardial cell protection activity (the result is shown in figure 15).
While the invention has been described in detail in the foregoing general description, embodiments and experiments, it will be apparent to those skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (6)
1. An extraction method of allium macrostemon medicinal material extract is characterized in that the extract is allium macrostemon amide A and allium macrostemon Bai Xianan B, and the structures of the allium macrostemon amide A and allium macrostemon Bai Xianan B are as follows:
1) Allium macrostemon Bai Xianan a:
2) Allium macrostemon Bai Xianan B:
the extraction method comprises the following steps:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 2 to 6 times at 60 to 90 ℃ with 5 to 10 times of 95 percent ethanol for 2 to 4 hours each time, combining the materials to obtain an extracting solution, recovering a solvent, and concentrating to obtain the total concentrated solution of the allium macrostemon medicinal materials;
2) Suspending the total concentrated liquid extract in 2-7 times of water for dilution, sequentially extracting with 2-7 times of petroleum ether, ethyl acetate and n-butanol for 2-5 times respectively, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
2. Extraction method according to claim 1, characterized in that it comprises the following steps:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 2 to 5 times at the temperature of between 65 and 85 ℃ with 6 to 9 times of 95 percent ethanol for 2 to 4 hours each time, combining the materials to obtain an extracting solution, recovering a solvent, and concentrating to obtain the total concentrated solution of the allium macrostemon medicinal materials;
2) Suspending the total concentrated liquid extract in 2-6 times of water for dilution, sequentially extracting with 2-6 times of petroleum ether, ethyl acetate and n-butanol for 2-4 times respectively, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
3. Extraction method according to claim 2, characterized in that it comprises the following steps:
1) Drying and crushing the allium macrostemon medicinal materials, heating and reflux-extracting the allium macrostemon medicinal materials for 3-4 times at 80 ℃ with 8 times of 95% ethanol for 2-4 hours each time, combining the extracting solutions, recovering the solvent, and concentrating to obtain the allium macrostemon medicinal material total concentrated solution;
2) Suspending the total concentrated liquid extract in 3-5 times of water for dilution, sequentially extracting with 3-5 times of petroleum ether, ethyl acetate and n-butanol for 3 times, and recovering solvent under reduced pressure to obtain petroleum ether part, ethyl acetate part and n-butanol part respectively;
3) Subjecting the ethyl acetate part to 100-200 mesh normal phase silica gel column chromatography, and sequentially using petroleum ether: gradient elution is carried out on ethyl acetate, and the specific proportion is as follows: detecting 100% petroleum ether, 100:1,50:1,20:1,10:1,5:1,4:1 and 100% ethyl acetate by thin layer chromatography, mixing eluents with similar composition, and recovering solvent under reduced pressure to obtain 8 elution parts;
4) Taking the following 4:1 eluting part, after dissolving by 1-3 times of volume of petroleum ether and ethyl acetate respectively, adding 1.5 times of mass of 200-300 meshes of extract, stirring, eluting by using a silica gel column chromatography with petroleum ether-ethyl acetate with the volume ratio of 10:1, monitoring in real time by using thin layer chromatography TLC, gradually increasing the polarity of an eluent until the volume ratio is 1:1, detecting to find that the compound basically flows out, stopping passing through a column, detecting and combining eluents with similar compositions through thin layer chromatography, and recovering the solvent under reduced pressure to obtain allium macrostemon amide A and allium macrostemon Bai Xianan B elution fractions.
4. The extraction method according to any one of claims 1 to 3, wherein the allium macrostemon amide A and B elution fractions obtained in step 4) are prepared by high performance liquid chromatography, and the allium macrostemon Bai Xianan A and B elution fractions are respectively eluted with 20-40% methanol 5-15L to obtain the compounds allium macrostemon amide A and allium macrostemon amide B.
5. The extraction method according to claim 4, wherein the allium macrostemon amide A elution fraction is prepared by high performance liquid chromatography and eluted with 30% methanol 10L to obtain allium macrostemon amide A.
6. The extraction method according to claim 5, wherein the allium macrostemon amide B elution fraction is prepared by high performance liquid chromatography and eluted with 25% methanol 10L to obtain allium macrostemon amide B.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110776103.7A CN113620834B (en) | 2021-07-08 | 2021-07-08 | Allium macrostemon medicinal material extract, extraction method, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110776103.7A CN113620834B (en) | 2021-07-08 | 2021-07-08 | Allium macrostemon medicinal material extract, extraction method, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113620834A CN113620834A (en) | 2021-11-09 |
| CN113620834B true CN113620834B (en) | 2023-12-08 |
Family
ID=78379383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110776103.7A Active CN113620834B (en) | 2021-07-08 | 2021-07-08 | Allium macrostemon medicinal material extract, extraction method, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113620834B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102186A (en) * | 1993-10-29 | 1995-05-03 | 沈阳医学院 | Determination and usage of new component of traditional Chinese medicine Chinese onion |
| CN101195582A (en) * | 2006-12-01 | 2008-06-11 | 黄振华 | Cinnamic amide derivant |
| WO2021021744A1 (en) * | 2019-07-29 | 2021-02-04 | Lee Chae | Method for improving digestive health |
| WO2021096813A1 (en) * | 2019-11-11 | 2021-05-20 | Brightseed, Inc | Extract, consumable product and method for enriching bioactive metabolite in an extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140046A1 (en) * | 2018-01-10 | 2019-07-18 | Brightseed, Inc. | Composition for modulating metabolism |
-
2021
- 2021-07-08 CN CN202110776103.7A patent/CN113620834B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102186A (en) * | 1993-10-29 | 1995-05-03 | 沈阳医学院 | Determination and usage of new component of traditional Chinese medicine Chinese onion |
| CN101195582A (en) * | 2006-12-01 | 2008-06-11 | 黄振华 | Cinnamic amide derivant |
| WO2021021744A1 (en) * | 2019-07-29 | 2021-02-04 | Lee Chae | Method for improving digestive health |
| WO2021096813A1 (en) * | 2019-11-11 | 2021-05-20 | Brightseed, Inc | Extract, consumable product and method for enriching bioactive metabolite in an extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113620834A (en) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109912680B (en) | Oleane-type triterpenoid saponin and extraction separation method and application thereof | |
| CN115010720B (en) | Chinese mugwort sesquiterpene dimer and pharmaceutical composition thereof, and preparation method and application thereof | |
| Abirami et al. | Isolation and Characterization of (4Z, 12Z)-Cyclopentadeca-4, 12-Dienone from Indian Medicinal Plant Grewia hirsuta and its Hyperglycemic Effect on 3 T3 and L6 Cell Lines | |
| Liu et al. | Anti-inflammatory abietanes diterpenes and triterpenoids isolated from Clinopodium polycephalum | |
| CN110746421B (en) | Extraction method and application of indole monoterpene compound | |
| CN113620834B (en) | Allium macrostemon medicinal material extract, extraction method, preparation method and application | |
| CN110256430B (en) | Nauclea officinalis new compound capable of promoting endothelial injury repair and preparation method and application thereof | |
| CN117003812A (en) | Rosin alkane type diterpenoid lactone compound, and preparation method and application thereof | |
| CN109400665B (en) | Method for preparing four triterpenoid compound reference substances from pubescent holly root | |
| CN114874098B (en) | Compound extracted and separated from glaucocalyxa, and preparation method and application thereof | |
| CN113861114A (en) | Morphinane and dibenzyl isoquinoline alkaloid compound and preparation method and application thereof | |
| CN113214214B (en) | Preparation method and application of terpenoid in Atractylodes lancea | |
| CN108703972A (en) | A kind of flavones-application of the saponin(e meroterpenoids compound in medicine preparation | |
| CN113527323A (en) | Method for extracting phenolic compounds from tung tree | |
| CN110204589B (en) | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament | |
| CN111377933B (en) | Alkaloid compound extracted from orychophragmus violaceus seeds as well as extraction method and application thereof | |
| CN102924557B (en) | Triterpenoid and its preparation method and application | |
| CN112300185B (en) | Alkaloid compound with reduced hepatotoxicity, and preparation method and application thereof | |
| CN114702388B (en) | Compound in rabdosia rubescens and extraction and separation method and application thereof | |
| CN113234084B (en) | Compound with anti-rotavirus activity in Meadowrue of Crane celebration and preparation method thereof | |
| CN113024494B (en) | Phenanthrene compound, preparation method and application | |
| CN113372407B (en) | Steroid saponin compound and preparation method and application thereof | |
| Shen et al. | Chemical components from Crotalaria pallida Ait. and their antioxidant activities | |
| CN109705074B (en) | Rehmannia furan aldehyde derivative with antioxidant activity and preparation method and application thereof | |
| CN105837450A (en) | Pharmaceutical composition of carbamazepine and medical application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |